KR101939430B1 - 산화된 인지질의 제형 및 투약형 - Google Patents
산화된 인지질의 제형 및 투약형 Download PDFInfo
- Publication number
- KR101939430B1 KR101939430B1 KR1020147008443A KR20147008443A KR101939430B1 KR 101939430 B1 KR101939430 B1 KR 101939430B1 KR 1020147008443 A KR1020147008443 A KR 1020147008443A KR 20147008443 A KR20147008443 A KR 20147008443A KR 101939430 B1 KR101939430 B1 KR 101939430B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- carrier
- capsule
- agent
- talc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161529989P | 2011-09-01 | 2011-09-01 | |
| US61/529,989 | 2011-09-01 | ||
| PCT/US2012/053533 WO2013033642A1 (en) | 2011-09-01 | 2012-08-31 | Formulations and dosage forms of oxidized phospholipids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140078641A KR20140078641A (ko) | 2014-06-25 |
| KR101939430B1 true KR101939430B1 (ko) | 2019-01-16 |
Family
ID=46964020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147008443A Expired - Fee Related KR101939430B1 (ko) | 2011-09-01 | 2012-08-31 | 산화된 인지질의 제형 및 투약형 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9254297B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2750668B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6109175B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101939430B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103874485B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012301602B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014004916B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2847218C (cg-RX-API-DMAC7.html) |
| EA (1) | EA029274B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2768266T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL231222B (cg-RX-API-DMAC7.html) |
| MX (1) | MX357759B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201400208PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013033642A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201401478B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8999960B2 (en) | 2008-10-08 | 2015-04-07 | Vascular Biogenics Ltd. | Oxidized thiophospholipid compounds and uses thereof |
| KR20110095288A (ko) | 2008-11-06 | 2011-08-24 | 바스큘라 바이오제닉스 리미티드 | 산화된 지질 화합물 및 이의 용도 |
| SG11201400208PA (en) * | 2011-09-01 | 2014-03-28 | Vascular Biogenics Ltd | Formulations and dosage forms of oxidized phospholipids |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| CN106999506A (zh) | 2014-11-26 | 2017-08-01 | 脉管生物生长有限公司 | 氧化脂质以及纤维化的治疗或预防 |
| US10597603B2 (en) | 2014-12-16 | 2020-03-24 | Polymer Ventures, Inc. | Oil recovery aid |
| PY1576960A (es) * | 2014-12-16 | 2017-12-01 | Polymer Ventures | Auxiliar de recuperación de aceite |
| JP6755530B2 (ja) * | 2016-09-02 | 2020-09-16 | 国立大学法人岩手大学 | 皮膚炎の予防又は治療用医薬組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010052718A1 (en) | 2008-11-06 | 2010-05-14 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
| WO2011083465A1 (en) * | 2010-01-05 | 2011-07-14 | Vascular Biogenics Ltd. | Treatment with vb-201 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1572226A (en) * | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
| US4970233A (en) * | 1987-08-04 | 1990-11-13 | Mchugh John E | Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC) |
| WO2002053092A2 (en) | 2001-01-04 | 2002-07-11 | Vascular Biogenics Ltd. | Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
| US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
| IL156015A0 (en) | 2000-11-24 | 2003-12-23 | Vascular Biogenics Ltd | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US20060258692A1 (en) * | 2002-10-31 | 2006-11-16 | Mark Pines | Quinazolinone compositions for regulation of gene expression related to pathological processes |
| CA2541382A1 (en) * | 2003-10-10 | 2005-04-21 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate and a statin |
| NZ553147A (en) | 2004-07-09 | 2010-07-30 | Vascular Biogenics Ltd | Improved process for the preparation of oxidized phospholipids |
| US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8999960B2 (en) | 2008-10-08 | 2015-04-07 | Vascular Biogenics Ltd. | Oxidized thiophospholipid compounds and uses thereof |
| SG11201400208PA (en) | 2011-09-01 | 2014-03-28 | Vascular Biogenics Ltd | Formulations and dosage forms of oxidized phospholipids |
-
2012
- 2012-08-31 SG SG11201400208PA patent/SG11201400208PA/en unknown
- 2012-08-31 JP JP2014528672A patent/JP6109175B2/ja not_active Expired - Fee Related
- 2012-08-31 EA EA201490544A patent/EA029274B1/ru not_active IP Right Cessation
- 2012-08-31 MX MX2014002362A patent/MX357759B/es active IP Right Grant
- 2012-08-31 CN CN201280049926.9A patent/CN103874485B/zh not_active Expired - Fee Related
- 2012-08-31 KR KR1020147008443A patent/KR101939430B1/ko not_active Expired - Fee Related
- 2012-08-31 ES ES12766751T patent/ES2768266T3/es active Active
- 2012-08-31 AU AU2012301602A patent/AU2012301602B2/en not_active Ceased
- 2012-08-31 CA CA2847218A patent/CA2847218C/en active Active
- 2012-08-31 WO PCT/US2012/053533 patent/WO2013033642A1/en not_active Ceased
- 2012-08-31 EP EP12766751.7A patent/EP2750668B1/en active Active
- 2012-08-31 BR BR112014004916-5A patent/BR112014004916B1/pt not_active IP Right Cessation
-
2013
- 2013-03-11 US US13/792,633 patent/US9254297B2/en not_active Expired - Fee Related
-
2014
- 2014-02-26 ZA ZA2014/01478A patent/ZA201401478B/en unknown
- 2014-02-27 IL IL231222A patent/IL231222B/en active IP Right Grant
-
2016
- 2016-02-08 US US15/018,158 patent/US20160220590A1/en not_active Abandoned
-
2018
- 2018-06-08 US US16/003,173 patent/US20190008880A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010052718A1 (en) | 2008-11-06 | 2010-05-14 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
| WO2011083465A1 (en) * | 2010-01-05 | 2011-07-14 | Vascular Biogenics Ltd. | Treatment with vb-201 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103874485B (zh) | 2017-06-09 |
| EA029274B1 (ru) | 2018-03-30 |
| WO2013033642A1 (en) | 2013-03-07 |
| EP2750668A1 (en) | 2014-07-09 |
| KR20140078641A (ko) | 2014-06-25 |
| ES2768266T3 (es) | 2020-06-22 |
| IL231222B (en) | 2018-01-31 |
| EP2750668B1 (en) | 2019-12-11 |
| AU2012301602A1 (en) | 2013-05-02 |
| MX357759B (es) | 2018-07-24 |
| MX2014002362A (es) | 2014-04-30 |
| BR112014004916B1 (pt) | 2021-12-21 |
| US20160220590A1 (en) | 2016-08-04 |
| HK1198430A1 (en) | 2015-04-24 |
| SG11201400208PA (en) | 2014-03-28 |
| AU2012301602B2 (en) | 2015-09-03 |
| IL231222A0 (en) | 2014-04-30 |
| CA2847218A1 (en) | 2013-03-07 |
| CA2847218C (en) | 2018-02-27 |
| US20130209555A1 (en) | 2013-08-15 |
| NZ621710A (en) | 2015-10-30 |
| ZA201401478B (en) | 2016-09-28 |
| JP2014525463A (ja) | 2014-09-29 |
| EA201490544A1 (ru) | 2014-08-29 |
| JP6109175B2 (ja) | 2017-04-05 |
| CN103874485A (zh) | 2014-06-18 |
| BR112014004916A2 (pt) | 2017-04-04 |
| US9254297B2 (en) | 2016-02-09 |
| US20190008880A1 (en) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2847218C (en) | Formulations and dosage forms of oxidized phospholipids | |
| AU2004308644B2 (en) | Pharmaceutical formulations of bisphosphonates | |
| WO2002011701A1 (en) | A controlled release pharmaceutical composition | |
| US10188623B2 (en) | Enhanced bioavailability of polyunsaturated fatty acids | |
| NL8520012A (nl) | Aceetaminofeen gelatinecapsule, die snelle aanvang van therapeutische activiteit na orale toediening oplevert. | |
| KR101830142B1 (ko) | 벤다무스틴의 경구 투약 형태 | |
| JP2015071542A (ja) | 固体分散体の製造方法 | |
| US20210046095A9 (en) | Self-emulsifying formulation of bisphosphonates and associated dosage forms | |
| HK1198430B (en) | Formulations and dosage forms of oxidized phospholipids | |
| NZ621710B2 (en) | Formulations and dosage forms of oxidized phospholipids | |
| WO2024043843A1 (en) | Pharmaceutical compositions comprising cdca as active ingredient and relevant excipients | |
| EP2600845B1 (fr) | Composition pharmaceutique contenant un extrait de serenoa repens | |
| JP7847966B2 (ja) | 医薬製剤およびその製造方法 | |
| KR101012903B1 (ko) | 나노입자 형성을 이용하는 리세드로네이트 경질캡슐 | |
| JP2009508855A (ja) | 医薬品用微粒子状脂質組成物 | |
| TW202128150A (zh) | 3'—[(2z)—[1—(3,4—二甲基苯基)—1,5—二氫—3—甲基—5—側氧基—4h—吡唑—4—亞基]肼基]—2'—羥基—[1,1'—聯苯基]—3—甲酸及其鹽配製物 | |
| WO2020218517A1 (ja) | 医薬製剤およびその製造方法 | |
| WO2009004592A1 (en) | Vancomycin compositions | |
| CN115279355A (zh) | 药物组合物 | |
| JP2009539940A (ja) | 微水溶性活性物質の経口製薬学的組成物 | |
| JPH0155245B2 (cg-RX-API-DMAC7.html) | ||
| HK1152477A (en) | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | |
| HK1200712B (en) | Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20230111 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20230111 |